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suggest a multi-pronged approach including focus groups and
surveys of physicians, implementation of clinical guidelines, and
ongoing feedback in an Israeli MCO.
ID2
OUTCOMES ASSOCIATED WITH ANTIFUNGAL DRUG
SWITCHING IN PATIENTS WITH SERIOUS CANDIDA
INFECTIONS
He J,Wang C, Grifﬁn B, Smith J, Mahoney A, Burleigh E
Solucient, Berkerley Heights, NJ, USA
OBJECTIVES: Serious candida infections have been treated with
a variety of patterns of antifungal drugs. This study focused on
the outcomes of hospitalized patients treated with antifungal
drugs and examined drug switching approaches in actual prac-
tice. METHODS: A retrospective study was conducted among a
population of 9746 serious candida infection patients treated
with antifungal drugs during the time period of February 2003
to June 2005. Data was collected from 441 hospitals out of the
Solucient® ACTrackertm database. Patients were categorized
into an adherence group with patients staying in aggressive drugs
(IV forms of amphotericin B, amphotericin B lipids, cancidas and
vfend) and a switching group with patients who switched from
aggressive drugs to non-aggressive and less expensive drugs (oral
forms only of amphotericin B, sporanox, diﬂucan & vfend).
Mortality and length of stay (LOS) of the two groups were com-
pared by Chi square and T test. Further analysis was followed
by using Logistics regression and ANCOVA analysis with con-
trolled inﬂuencing factors such as co-morbidities. RESULTS: The
drug switching patients group was found to have signiﬁcantly
higher mortality rate (0.246 vs 0.160, Chi = 29.68, p < 0.001)
and longer LOS (36.45 vs 27.73, t = 7.67, p < 0.001) as com-
pared to adherence group. The higher mortality in switching
group was supported by Logistic regression results with the 
following confounding factors controlled: age (OR 1.013,
CI:1.009–1.017), septicemia (OR 1.231, CI:1.055–1.451),
kidney disease(OR 1.288, CI:1.091–1.52), ER(OR 1.362,
CI:1.083–1.712) and other candida (OR 1.440,
CI:1.039–1.996). The extended LOS also was found by using
ANCOVA with confounding factors adjusted including mycoses,
ER admission, Medicare payment. CONCLUSIONS: The study
demonstrated that switching aggressively treated patients to
cheaper and less aggressive drugs caused higher mortality and
extended hospital stay. More extensive clinical and economic
outcome studies are needed to understand antifungal drug treat-
ment in candida infection patients.
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TRENDS IN HIV TREATMENT EXPERIENCE AND OUTCOMES
AS OBSERVED IN A SAMPLE OF PATIENTS FROM A US
CLINICAL DATABASE
Martin SC, Stellhorn R, Nuyts G
Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA
OBJECTIVES: Describe US treatment experience trends, shifts
in employment status, insurance, and CD4 counts of HIV/AIDS
patients since the introduction of highly active antiretroviral
therapy (HAART) in 1996. METHODS: HIV-infected patients
(n = 3203) treated at US clinics from 1996–2004 as part of the
HIV Insight database* were studied. Longitudinal patient
records were analyzed to track the changing distribution of anti-
retroviral treatment experience by year. Patients having at least
six months of follow-up and enrollment in the reporting year
were classiﬁed into four treatment experience groups: Nucleo-
side Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside
Reverse Transcriptase Inhibitors (NNRTI), Protease Inhibitor
(PI), and 3-class experience. Demographic shifts were observed
for: employment and disability status, and primary insurance
type. CD4 counts were examined by treatment experience level.
RESULTS: Of the 3203 patients with active enrollment, 2552
were treated. Average follow-up was 3.84 and 4.33 years, respec-
tively. The percentage of patients with treatment experience
increased substantially in all 4 groups (1996–2004): NRTI (48%,
98%), NNRTI (4%, 67%), PI (25%, 63%), 3-class (<1%, 36%).
The percentage of patients working (part/full-time) increased
from 49% to 62% from 1996 to 2004. The percentage of dis-
abled patients decreased from 22% to 15%. Primary insurance
coverage for treated patients was distributed as follows
(1996–2004): Private insurance (50%, 60%), Medicare (10%,
7.4%), Medicaid (30%, 20%), AIDS Drug Assistance Programs
(ADAP) (2.7%, 5.0%), and Other (7.5%, 8.4%). Lower CD4
counts correspond with more treatment experienced patients.
CONCLUSIONS: While increased use of HAART therapy cor-
responds with better employment status and increased private
insurance, patients who have more treatment experience have
lower CD4 counts, signaling a need for more effective treatment
options. *Includes data from the CDC’s HIV Outpatient Study,
and other US HIV care-sites funded by Cerner Corporation. The
ﬁndings and conclusions are the authors’ and don’t represent the
views of the CDC/US DHHS.
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OBJECTIVES: There is a paucity of published research address-
ing how the Infectious Disease Society of America guidelines for
empiric treatment of CAP are implemented in clinical practice.
The current study was designed to describe antibiotic treatment
patterns among Medicare managed care patients with CAP
treated in ambulatory settings in light of these guidelines.
METHODS: This study used claims data from a Medicare
managed care organization located throughout geographically
diverse regions of the US. Patients with pneumonia treated with
any antibiotic in ambulatory settings during 2004 were retro-
spectively identiﬁed via ICD-9CM codes (481–486). Recent
antibiotic use was identiﬁed through NDC and J codes, and
deﬁned as receipt of any antibiotics within 90 days prior to the
date of diagnosis. Individuals were divided into four groups as
per guidelines: G1) previously healthy without recent antibiotics;
G2) previously healthy with recent antibiotics; G3) with comor-
bidities (including COPD, diabetes, renal or congestive heart
failure, or malignancy) and without recent antibiotics; AND G4)
with comorbidities and recent antibiotics. RESULTS: Of 2186
patients identiﬁed, 59% had comorbidities. The mean age was
76.6 years and 61% were female. Among G1 patients (n = 661),
guideline compliance was 41% (recommended treatment: a
macrolide or doxycycline). For G2 patients (n = 230), guideline
compliance was 40% (recommended treatment: a respiratory
quinolone alone, or an advanced macrolide plus amoxicillin or
augmentin). A high compliance rate was observed among G3
patients with comorbidities and without recent antibiotics (n =
861) (72%; recommended treatment: an advanced macrolide or
respiratory quinolone). For G4 patients with comorbidities and
recent antibiotics (n = 434), guideline compliance was 39% (rec-
ommended treatment: a respiratory quinolone alone or advanced
macrolide plus beta-lactam). CONCLUSION: These data,
reﬂecting a period shortly after the CAP guidelines were pub-
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lished, illustrate that there is room for improvement regarding
choice of empiric antimicrobial treatment.
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THE INDIRECT COST BURDEN OF MIGRAINE AMONG
SEVERAL LARGE U.S. EMPLOYERS
Hawkins K1, Rupnow M2,Wang S3
1Thomson-Medstat, Ann Arbor, MI, USA, 2Ortho-McNeil Janssen
Scientiﬁc Affairs, LLC,Titusville, NJ, USA, 3Thomson-Medstat,
Cambridge, MA, USA
OBJECTIVES: To estimate the indirect cost burden of migraine
on U.S. employers, in terms of workplace absence, short-term
disability (STD) and workers compensation (WC) payments.
METHODS: The data source for this study was the MEDSTAT
Health and Productivity Management database, composed of
medical, pharmaceutical, enrollment, workplace absence, STD,
and WC information on employees for 10 large employers in the
U.S. for the calendar years 2002 and 2003. Subjects with a diag-
nosis for migraine or use of a migraine-speciﬁc abortive drug
were identiﬁed as the migraine cohort. A random sample of
patients without migraine was propensity score matched, based
on demographic characteristics and comorbidity index, to the
migraine cohort to yield a matched control group. Indirect costs
between migraine and matched control cohorts were compared
to derive the indirect burden of illness attributable to migraine.
RESULTS: The analyses included 5037 subjects in the migraine
cohort, and equal number of subjects in the control group. The
mean age was 39 (SD = 9.3), and 71% were female. After match-
ing, the cohorts were similar with respect to age, gender, geo-
graphic region, urban residence, insurance type, the number of
psychiatric diagnostic groups and Charlson comorbidity index.
The migraine cohort incurred signiﬁcantly higher indirect costs
than the control cohort in all categories (absence, STD, and WC).
Total indirect costs were $2834 per patient per year (PPPY)
higher in the migraine group ($4453 versus $1619 PPPY in the
control group; p < 0.001). Absence costs made up the largest
component of this difference at 75%, with STD and WC making
up 21% and 4%, respectively. CONCLUSIONS: The migraine
cohort was associated with signiﬁcantly higher indirect costs
compared to a matched control based on recent data from a
sample of commercially insured individuals. This data suggest
that US employers are bearing a considerable indirect cost
burden as a consequence of migraine.
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EVALUATIONS OF THE PRESCRIBED DAILY DOSES OF
TRANSDERMAL FENTANYL AND TRANSDERMAL
BUPRENORPHINE IN CANCER AND NON-CANCER PATIENTS
IN GERMANY: RESULTS FROM A RETROSPECTIVE DATABASE
ANALYSIS
Haerdtl G1, Niemann U1, Nuijten MC2, Poulsen Nautrup B3
1MAIX Market Research & Consulting, Aachen, Germany, 2Erasmus
University Rotterdam, Rotterdam,The Netherlands, 3Gruenenthal
GmbH, Aachen, Germany
OBJECTIVES: In a previously published study dose increases
have been shown to be signiﬁcantly more pronounced with trans-
dermal (TD) fentanyl compared to TD buprenorphine. The
purpose of this study was not only to re-evaluate these results
because of the high economic impact but also to qualitatively
evaluate the dose development as a measure of ease of dosing
and dose adjustment during therapy with TD fentanyl and TD
buprenorphine in cancer and non-cancer patients. METHODS:
Retrospective analysis of the German “IMS Disease Analyzer—
mediplus” database covering patient data from May, 2002 to
April, 2005. Patients on long-term treatment (≥3 months) with
TD fentanyl or TD buprenorphine had received similar analgesic
pre-medication and were considered as identical cohorts with
similar pain intensity, expecting comparable drug utilization pat-
terns. Dose changes over the treatment duration were evaluated
qualitatively and quantitatively. RESULTS: From dose changes
over the whole treatments mean daily dose increases per patient
were calculated to be 0.47% (TD fentanyl) and 0.19% (TD
buprenorphine) in cancer patients, and 0.25% and 0.10% in
non-cancer patients, respectively. Despite the overall dose
increases, qualitative evaluations revealed dose changes in both
directions, i.e. dose increases and decreases during therapy in
30.6% of TD fentanyl and 11.8% of TD buprenorphine patients
with cancer pain. In non-cancer pain 22.7% of TD fentanyl and
13.1% of TD buprenorphine patients had alternating dose
changes. All differences between TD fentanyl and TD buprenor-
phine were statistically signiﬁcant (p < 0.05). CONCLUSIONS:
The more pronounced dose increases with TD fentanyl in com-
parable pain patients conﬁrm previous ﬁndings, indicating a
higher tolerance development with TD fentanyl. Regardless of
the overall dose increases, alternating dose changes, i.e. changes
in both directions are more frequent with TD fentanyl. This also
suggests a less convenient and more complicated dose adjustment
with TD fentanyl compared to TD buprenorphine.
ND3
A DESCRIPTION OF OFFICE VISIT RATES AND PRESCRIPTION
USE FOR INSOMNIA AMONG RECIPIENTS OF A STATE
MEDICAID PROGRAM
Roy AN, Smith MJ
West Virginia University, Morgantown, WV, USA
OBJECTIVE: Insomnia is a common condition affecting millions
of people across the United States. Most often it occurs in con-
junction with other illnesses and is chronic in at least one-third
of its cases. Studies have shown insomnia to be an underre-
ported, underdiagnosed and undertreated problem. The purpose
of this study is to report the recent patterns of health services
and prescription use for insomnia among a state Medicaid pop-
ulation. METHODS: The design was a cross-sectional, descrip-
tive study using Medicaid administrative claims data from
calendar year 2003. Recipients with either a claim paid for a
medical service with a diagnosis of insomnia, or a prescription
claim with an NDC number for zolpidem, temazepam, estazo-
lam, triazolam, quazepam, ﬂurazepam, or zaleplon were
selected. Rates of medical services use were calculated based on
state recipient population ﬁgures for ﬁscal year 2002–2003.
Dollars paid were from the perspective of Medicaid. RESULTS:
There was a total sample of 13,161 recipients identiﬁed with
insomnia, at a rate of 36.9 per 1000 recipients. A substantial
majority of medical services utilization occurred in a physician
ofﬁce or outpatient clinic, with very few visits for this condition
occurring in the emergency department or inpatient setting. The
overall rate of ofﬁce/clinic visits was 22.4 per 1000 recipients.
The highest ofﬁce/clinic visit rates by demographic groups
occurred among recipients between 45 to 64 years of age (66.8
visits per 1000), females (22.5 visits per 1000), and whites (21.5
visits per 1000). The average cost per ofﬁce/clinic visit was
approximately $91. Among the prescription claims for drugs
approved to treat insomnia, roughly 98 percent were for 
zolpidem. This particular drug cost Medicaid approximately 
$65 per claim. CONCLUSION: Ofﬁce visit use for the treatment
of insomnia varied by demographic groups. Zolpidem was 
used more extensively than other drugs approved for this 
condition.
